Stem Cell Clinic

R3 International Offering New Program for Stem Cell Therapy for Liver Failure in Mexico – Yahoo Finance

R3 International is now offering a new program for stem cell therapy for liver failure in Mexico. The program offers up to 200 million stem cells, with the cost starting at only $8975.

SAN DIEGO, June 29, 2020 /PRNewswire-PRWeb/ -- R3 International is now offering a new program for stem cell therapy for liver failure in Mexico. The program offers up to 200 million stem cells, with the cost starting at only $8975.

Millions of individuals suffer from chronic liver disease, which occurs due to a number of causes such as hepatitis, cirrhosis, metabolic diseases, and other conditions. All too often, conventional therapies fail to provide the desired result.

Stem cell therapy has been shown in several studies to produce beneficial results for liver failure. This includes a study of 43 patients from 2012 in Stem Cells and Translational Medicine noting significant increase in survival rates, along with no adverse events.

In its new program, R3 International uses the same weight based protocol. Each treatment provides up to 50 million stem cells at a time, with the treatment occurring at the stem cell therapy clinic in Tijuana Mexico. To date, hundreds of patients have received stem cell therapy in Mexico with R3 for a variety of conditions. No adverse events have been reported, and outcomes have been sensational for organ failure, arthritis, diabetes, dementia, stroke, stem cells for Lyme disease, Crohns and many more.

In order to receive treatment, patients start with a free phone consultation with the licensed, experienced stem cell doctor from R3 International. After the consult and review of medical records, the doctor provides a treatment recommendation. Then the dedicated patient concierge representative will assist with travel logistics and transportation from San Diego to the clinic is provided.

Simply call (888) 988-0515 to schedule the phone consultation and learn about options for treatment.

SOURCE R3 Stem Cell International

Original post:
R3 International Offering New Program for Stem Cell Therapy for Liver Failure in Mexico - Yahoo Finance

Pembrolizumab Approved for First-Line Treatment of Patients With Colorectal Cancer and Key Mutations – AJMC.com Managed Markets Network

The decision comes almost exactly a month after results from KEYNOTE-177 were presented at the annual meeting of the American Society of Clinical Oncology.

Merck, which makes pembrolizumab, sold as Keytruda, announced the approval in a statement.

The approval covers patients who have microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer and is based on results of KEYNOTE-177, a phase 3 trial of 307 patients that found the programmed cell death-1 (PD-1) inhibitor trimmed the risk of death of disease progression 40% compared with chemotherapy, which is the current standard of care (HR = 0.60, 95% CI: 0.45-0.80, P = .0004).

Results presented at ASCO showed that pembrolizumab doubled progression-free survival in these colorectal cancer patients, from 8.2 months to 16.5 months. Lead study author Thierry Andr MD, of the Sorbonne Universit and Hpital Saint Antoine in Paris, said at the time that the findings would change the standard of care. No medical treatment has shown such an improvement, Andr said.

Discussant Michael Overman, MD, of The University of Texas MD Anderson Cancer Center, agreed and said the tumors treated in the study were particularly good candidates for immunotherapy. From now on, he said, It is critical that we test all colorectal cancer patients for mismatch repair or microsatellite status.

The approval came less than a month after Merck submitted a supplemental Biologics License Application, which was handled through FDAs Real-Time Oncology Review pilot program. According to the Merck statement, the approval was reviewed under Project Orbis, an initiative of the FDA Oncology Center of Excellence that allows for concurrent submission and review of oncology drugs among its international partnersin this case, regulators in Australia, Canada, and Switzerland.

Todays approval has the potential to change the treatment paradigm for the first-line treatment of patients with MSI-H colorectal cancer, based on the important findings from KEYNOTE-177 that showed Keytruda monotherapy demonstrated superior progression-free survival compared to standard of care chemotherapy, Roy Baynes, MD, PhD, senior vice president and head of global clinical development, chief medical officer for Merck Research Laboratories, said in the statement.

At ASCO, Andr trumpeted the value of biomarker-driven research, and Baynes did the same today. Our commitment to pursuing biomarker research continues to help us bring new treatments to patients, he said, particularly for those who have few available options.

Immune-related adverse events can include pneumonitis, colitis, hepatitis, skin reactions, renal dysfunction, and endocrinological abnormalities. Patients taking the PD-1 inhibitor may experience solid organ transplant rejection or complications from stem cell transplant.

Luis A. Diaz, MD, head of the division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center. said in the statement that patients with colorectal cancer and the genetic mutations in the study have historically faced poor outcomes, and until today, chemotherapy-containing regimens were the only FDA-approved first-line treatment options.

About 5% of metastatic colorectal cancer patients have MSI-H/dMMR. Pembrolizumabs effectiveness when this mutation is present is well-recognized, and led to FDAs firsttissue-agnostic approvalin May 2017.

See original here:
Pembrolizumab Approved for First-Line Treatment of Patients With Colorectal Cancer and Key Mutations - AJMC.com Managed Markets Network

Genespire and the San Raffaele Telethon Institute for Gene Therapy announce publication in Nature Biotechnology on enhanced gene editing technique in…

June 30, 2020 07:00 ET | Source: Genespire

Genespire and the San Raffaele Telethon Institute for Gene Therapy announce publication in Nature Biotechnology on enhanced gene editing technique in hematopoietic stem cells

Italy, Milan, 30 June 2020: The San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) and Genespire, a gene therapy company developing transformative therapies for genetic diseases, announce today the publication of data highlighting progress in the development of an improved targeted gene replacement technology in human hematopoietic stem cells (HSCs) in Nature Biotechnology.

The paper, entitled Efficient gene editing of human long-term hematopoietic stem cells validated by clonal tracking, outlines technology developed by Pr. Luigi Naldini and his team at SR-Tiget, which is included in the strategic alliance with Genespire. It shows increased homology directed recombination (HDR) efficiency in HSCs by forcing cell-cycle progression and transiently upregulating components of the HDR machinery. The findings are validated by clonal tracking of the edited HSCs in experimental transplantation models, which shows improved polyclonal engraftment by long-term repopulating HSCs.

People with genetic diseases affecting the hematopoietic lineage may benefit from corrective targeted gene therapy in HSCs. These cells are self renewing and can differentiate into all the cell types of the hematopoietic lineage, therefore providing the potential for a one-time therapy. As compared to standard gene replacement approaches, gene editing corrects the disease-causing mutation in situ, restoring both function and physiological expression control of the affected gene. In principle, this targeted strategy may fulfill the goal of precision medicine at the most stringent genetic level. Its realization in HSCs, however, has been hampered until now by low efficiency of HDR-driven repair, likely because of the quiescent state of the more primitive progenitors. Use of the improved gene editing technology developed by SR-Tiget has been shown to yield a greater percentage of gene-edited HSCs and increased clonality, or the number of modified cells transplanted and engrafted in the recipient. In a clinical setting this should lead to increased hematopoietic cells chimerism in the patient receiving the corrective HSC therapy, and could accelerate the hematopoietic recovery after conditioning and increase the size, long-term stability, and safety of the engineered cell graft.

This approach can be applied to genetic diseases originating in the hematopoietic lineage, including primary immune deficiencies (PIDs), a key area of focus for Genespire. Genespire will continue to work with SR-Tiget and apply this technology to its future pipeline of gene therapies.

Julia Berretta, Chief Executive Officer of Genespire, commented: The focus of Genespires alliance with SR-Tiget is to research and develop novel gene therapies, addressing severe diseases with high unmet medical need. We are pleased with the publication of these data in Nature Biotechnology, which provide valuable insights into this pioneering technology developed by SR-Tiget, and we look forward to our future work with them to translate cutting edge science into transformational therapies.

Professor Luigi Naldini, Director of SR-Tiget and scientific co-founder of Genespire, said Our findings elucidate and overcome two main biological barriers to efficient HDR-mediated gene editing in HSCs, and show by clonal tracking that our enhanced editing protocol preserves their multilineage and self-renewal capacity long term after serial transplant. We look forward to our future work with Genespire to explore its potential in primary immunodeficiencies.

The full publication details are below and can be accesed online here.

Efficient gene editing of human long-term hematopoietic stem cells validated by clonal tracking Samuele Ferrari, Aurelien Jacob, Stefano Beretta, Giulia Unali, Luisa Albano, Valentina Vavassori, Davide Cittaro, Dejan Lazarevic, Chiara Brombin, Federica Cugnata, Anna Kajaste-Rudnitski, Ivan Merelli, Pietro Genovese and Luigi Naldini

Enquiries:

About Genespire

Genespire is a biotechnology company focused on the development of transformative gene therapies for patients affected by genetic diseases, particularly primary immunodeficiencies and inherited metabolic diseases. Based in Milan, Italy, Genespire was founded in March 2020 by the gene therapy pioneer Prof. Luigi Naldini and Dr. Alessio Cantore, Fondazione Telethon and Ospedale San Raffaele. It is a spin-off of SR-Tiget, a world leading cell and gene therapy research institute and is backed by Sofinnova Partners. http://www.genespire.com

About SR-Tiget

Based in Milan, Italy, the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) is a joint venture between the Ospedale San Raffaele and Fondazione Telethon. SR-Tiget was established in 1995 to perform research on gene transfer and cell transplantation and translate its results into clinical applications of gene and cell therapies for different genetic diseases. Over the years, the Institute has given a pioneering contribution to the field with relevant discoveries in vector design, gene transfer strategies, stem cell biology, identity and mechanism of action of innate immune cells. SR-Tiget has also established the resources and framework for translating these advances into novel experimental therapies and has implemented several successful gene therapy clinical trials for inherited immunodeficiencies, blood and storage disorders, which have already treated >115 patients and have led through collaboration with industrial partners to the filing and approval of novel advanced gene therapy medicines.

Go here to read the rest:
Genespire and the San Raffaele Telethon Institute for Gene Therapy announce publication in Nature Biotechnology on enhanced gene editing technique in...

Covid-19 outbreak imparts profitable opportunities to Stem Cell Therapy market; demand to remain high post pandemic – Jewish Life News

2014-2029 Report on Global Stem Cell Therapy Market By Player, Region, Type, Application And Sales Channel the new research report adds in kandjmarketresearch.com research reports database. Complete report On Stem Cell Therapy Research Report Spread Across 109 Pages, With Summarizing Top Companies and Stem Cell Therapy with Tables and Figures.

Market Overview

The global Stem Cell Therapy market has been studied by a set of researchers for a defined forecast period of 2014 to 2029. This study has provided insights to the stakeholders in the market landscape. It includes an in-depth analysis of various aspects of the market. These aspects include an overview section, with market segmentation, regional analysis, and competitive outlook of the global Stem Cell Therapy market for the forecast period. All these sections of the report have been analyzed in detail to arrive at accurate and credible conclusion of the future trajectory. This also includes an overview section that mentions the definition, classification, and primary applications of the product/service to provide larger context to the audience to this report.

Market Dynamics

The report on the global Stem Cell Therapy market includes a section that discusses various market dynamics that provide higher insight in the relationship and the impact of change these dynamics hold on the market functioning. These dynamics include the factors that are providing impetus to the market over the forthcoming years for growth and expansion. Alternatively, it also includes factors that are poised to challenge the market growth over the forecast period. These factors are expected to reveal certain hidden trends that aid in the better understanding of the market over the forecast period.

The Final Report Will Include the Impact of COVID 19 Analysis in This Stem Cell Therapy Industry.

Get Free Sample Report on Stem Cell Therapy @: https://www.kandjmarketresearch.com/sample-request/328640

Key Players

The global Stem Cell Therapy market report has provided a profiling of significant players that are impacting the trajectory of the market with their strategies for expansion and retaining of market share.

Leading players of Stem Cell Therapy including:

Market split by Type, can be divided into:

Market split by Application, can be divided into:

Do You Have Any Query or Specific Requirement? Ask to Our Trade Expert @ https://www.kandjmarketresearch.com/enquiry/328640

Market Segmentation

The global Stem Cell Therapy market has been studied for a detailed segmentation that is based on different aspects to provide insight in the functioning of the segmental market. This segmentation has enabled the researchers to study the relationship and impact of the growth chart witnessed by these singular segments on the comprehensive market growth rate. It has also enabled various stakeholders in the global Stem Cell Therapy market to gain insights and make accurate relevant decisions. A regional analysis of the market has been conducted that is studied for the segments of North America, Asia Pacific, Europe, Latin America, and the Middle East & Africa.

Research Methodology

The global Stem Cell Therapy market has been analyzed using Porters Five Force Model to gain precise insight in the true potential of the market growth. Further, a SWOT analysis of the market has aided in the revealing of different opportunities for expansion that are inculcated in the market environment.

Market split by Sales Channel, can be divided into:

Market segment by Region/Country including:

Read More Detailed Information regarding Stem Cell Therapy Industry with Covid-19 Updates @: https://www.kandjmarketresearch.com/reports/328640-2014-2029-report-on-global-stem-cell-therapy-market-by-player-region-type-application-and-sales-channel

About Us:

Kandjmarketresearch.com is part of the KnowledgeNJournals Research Firm which provides premium progressive market research reports, statistical surveying, analysis & forecast data for industries and governments from hundreds of publishers around the world. We have almost all top publishers reports in our collection to provide you with instant online access to the worlds most complete and fresh database on a Daily Basis. We are at KandJ Market Research are inspired to help our clients grow by providing appropriate business insight with our huge market intelligence source.

If you have any special requirements for the report, please let us know and we will offer you a customized report on separate regional or country-level reports.

Contact us:

KandJ Market Research

(Part of KnowledgeNJournals Research)

E-mail: [emailprotected]

Website: https://www.kandjmarketresearch.com

Call us: +1 661 636 6162 | +91 932 580 2062

Go here to read the rest:
Covid-19 outbreak imparts profitable opportunities to Stem Cell Therapy market; demand to remain high post pandemic - Jewish Life News

Research Antibodies Market To Reach USD 5.33 Billion By 2027 | Reports and Data – GlobeNewswire

June 29, 2020 17:00 ET | Source: Reports and Data

New York, June 29, 2020 (GLOBE NEWSWIRE) -- The globalresearch antibodies marketis expected to reach USD 5.33 Billion by 2027, according to a new report by Reports and Data. Rising research activities in the field of stem cells is a significant factor driving the growth of the market. Stem cells have the capability of discerning and regenerating various kinds of cells in the human body. These cells possess the potential to cure life-threatening diseases such as oncological and blood-related disorders. Cord blood stem cells find application in the treatment of more than 80 blood-related ailments, such as Sickle Cell Disease. It is projected that over 27 million babies across the globe are born with some kind of blood disorder. As per the World Health Organization, in 2008, 100,000 children were found to be suffering from thalassemia in India.

Increased funding for research and development activities is instrumental in driving the growth of the market. Investment in the healthcare R&D by the US has witnessed a growth of 18.1% between the years 2014 and 2017. In the year 2017, in the US, the overall expenditure on healthcare R&D was USD 182.30 billion. Besides, according to the 2016 financial statements of Celgene Corporation, a leading biopharmaceutical firm, the R&D expenditure grew by USD 772.8 million (21.0% more than 2015 expenses) in 2016 to USD 4.47 billion. Also, a USD 892.9 million of R&D asset acquisition spending, comprising a USD 625.0 million purchase of Engmab AG, a private firm engaged in T-cell bispecific antibodies, added to the overall R&D expenses of the Celgene.

However, cost-prohibitive research antibodies and issues related to the quality of nontherapeutic antibodies may create hindrances in the growth of the market in the upcoming years.

Get FREE Sample Copy with TOC of the Report to understand the structure of the complete report@ https://www.reportsanddata.com/sample-enquiry-form/3270

COVID-19 Impact As the global economies are experiencing the negative impact of the Covid-19 pandemic, organizations are suffering losses, among various other challenges. Nevertheless, firms in the pharmaceutical industry are of immense importance in combatting the pandemic and are witnessing positive growth in the contagious disease landscape with the race for treatment approval therapy gaining momentum.

In April 2020, the ICMR (Indian Council of Medical Research) announced that it would fast-track funding proposals intended for immunology approaches for the treatment of coronavirus, a step to bridge the research gap in the country to combat the pandemic.

Further key findings from the report suggest

BUY NOW (Customized Report Delivered as per Your Specific Requirement)@ https://www.reportsanddata.com/checkout-form/3270

For the purpose of this report, Reports and Data have segmented the global research antibodies market on the basis of product, antibody type, technology, application, end-users, and region:

ProductOutlook (Revenue, USD Million; 2017-2027)

Antibody TypeOutlook (Revenue, USD Million; 2017-2027)

TechnologyOutlook (Revenue, USD Million; 2017-2027)

ApplicationOutlook (Revenue, USD Million; 2017-2027)

Industry VerticalOutlook (Revenue, USD Million; 2017-2027)

To identify the key trends in the industry, click on the link below: https://www.reportsanddata.com/report-detail/research-antibodies-market

Regional Outlook (Revenue, USD Million; 2017-2027)

Take a Look at our Related Reports:

E-Prescribing Market: https://www.reportsanddata.com/report-detail/e-prescribing-market

Mobile Health (mHealth) Market: https://www.reportsanddata.com/report-detail/mobile-health-mhealth-market

Artificial Intelligence in Drug Discovery Market: https://www.reportsanddata.com/report-detail/artificial-intelligence-in-drug-discovery-market

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help clients make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

Visit link:
Research Antibodies Market To Reach USD 5.33 Billion By 2027 | Reports and Data - GlobeNewswire

Benefit From CD19 CAR T-Cell Therapy in Relapsed/Refractory B-Cell ALL – Hematology Advisor

Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy yields a high rate of complete remission (CR) for patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), including those who have high-risk features, according to a study published in Blood Advances.

The phase 1/2 study (IM19CAR-T; ClinicalTrials.gov Identifier: NCT03173417), conducted at the Lu Daopei Hospital in China, aimed to assess the efficacy and safety of anti-CD19 CAR T cells in patients with R/R B-ALL, including patients with the following high-risk features: extramedullary disease, TP53 mutation, BCR-ABL1+, or relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT).

The primary endpoints measured short-term efficacy (CR and minimum residual disease [MRD]-negative CR on day 30) and safety (CAR T-cellrelated cytokine release syndrome and neurotoxicity). The secondary endpoints included 1-year overall survival (OS) and leukemia-free survival (LFS) after CAR T-cell therapy.

Of the 115 patients with CD191 B-ALL who were enrolled in the study, 110 participants (62% male) were successfully infused with anti-CD19 CAR T cells. The median patient age was 12 years (range, 2-61 years); however, most patients (71 participants) were between ages 2 and 14 years.

Overall, 93% of patients achieved a morphologic CR. Among these, 87% became MRD-negative at 30 days. Efficacy was observed across all high-risk feature subgroups as well. Among the 110 patients, the 1-year LFS and OS was 58% and 64%, respectively.

A subset of 75 patients (73.5%) received allo-HSCT after CAR T-cell infusion. These patients demonstrated longer LFS (76.9% vs 11.6%; P <.0001) and OS (79.1% vs 32.0%; P <.0001) than those who received CAR T-cell therapy alone, and this was confirmed in a multivariate analysis (hazard ratio [HR], 16.546).

Notably, patients with TP53 mutation had a lower OS (51.9% vs 89.0%; P <.0001 and LFS (42.4% vs 82.6%; P =.0002) than those without TP53 mutation, and this was also confirmed in a multivariate analysis (HR, 0.235).

Age did not significantly affect CR rate, OS, or LFS when comparing patients aged 2 to 14 years with those older than 14 years.

The authors reported mild cytokine release syndrome and neurotoxicity. Cytokine release syndrome occurred in most patients (92%); however, most of these cases (76%) were grade 1 to 2, with a minority (16%) having grade 3 to 4. Overall, neurotoxicity was less common (any grade, 21%; grade 2 to 3, 14%; grade 1, 7%).

The primary limitations of the study were that it was conducted at a single center and the allo-HSCT recipients were not randomly selected.

Despite the high rates of CR, the authors concluded, The relapse rate for subgroups with high-risk features after CAR T-cell treatment alone remains high, and CAR T-cell therapy followed by subsequent consolidative allo-HSCT has showed better LFS and OS in our study. However, the benefit of a subsequent allo-HSCT transplant requires confirmation with randomized allocation.

Disclosures: Some authors have declared affiliations with the pharmaceutical industry. Please refer to the original study for a full list of disclosures.

Zhang X, Lu X, Yang J, et al. Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features. Blood Adv. 2020;4(10):2325-2338.

See the original post here:
Benefit From CD19 CAR T-Cell Therapy in Relapsed/Refractory B-Cell ALL - Hematology Advisor